Oncology Institute (TOIIW) Non-Current Debt (2020 - 2026)

Oncology Institute has reported Non-Current Debt for 6 years, with the latest figure at $78.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt rose 6.38% year-over-year to $78.6 million; the trailing twelve-month figure through Mar 2026 stood at $78.6 million (up 6.38% YoY), and the FY2025 full-year result was $77.4 million, down 16.89% from the prior year.
• Non-Current Debt for Q1 2026 stood at $78.6 million, up from $77.4 million in the prior quarter.
• The five-year high for Non-Current Debt was $93.1 million in Q4 2024, with the low at $73.9 million in Q1 2025.
• Historically, Non-Current Debt has averaged $82.8 million across 5 years, with a median of $82.1 million in 2023.
• Annual changes were most pronounced in 2023 — Non-Current Debt gained 7.82% — and 2025, when it declined 16.89%.
• Oncology Institute's Non-Current Debt stood at $80.6 million in 2022, then advanced by 7.7% to $86.8 million in 2023, then gained by 7.26% to $93.1 million in 2024, then decreased by 16.89% to $77.4 million in 2025, then advanced by 1.56% to $78.6 million in 2026.
• The last three Non-Current Debt figures came in at $78.6 million (Q1 2026), $77.4 million (Q4 2025), and $76.2 million (Q3 2025), per Business Quant data.